Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis

Changhong Li,Yijun Han,Xinyi Li,Hua Zhang,Zhongqiang Yao,Jiansuo Zhou,Rong Mu,Jinxia Zhao
DOI: https://doi.org/10.1016/j.semarthrit.2024.152483
IF: 5.431
2024-06-01
Seminars in Arthritis and Rheumatism
Abstract:Objectives Rapidly progressive interstitial lung disease (RPILD) in patients with dermatomyositis (DM) significantly impacts prognosis, leading to high mortality rates. Although several indicators have been demonstrated to strongly correlate with the risk of developing RPILD, their clinical utility still needs to be investigated. The objective of this study was to investigate the clinical significance of soluble CXCL16 (sCXCL16) in DM patients complicated with RPILD. Methods Serum sCXCL16 was measured by enzyme-linked immunosorbent assay in 96 patients with DM and 55 matching healthy donors. Correlations between sCXCL16 levels and clinical features, laboratory examinations and the predictive value of baseline sCXCL16 level for RPILD were analysed. Results The serum sCXCL16 levels were significantly higher in patients with DM (n=96, 3.264±1.516 ng/mL) compared with healthy donors (n=55, 1.781±0.318 ng/mL), especially in DM complicated with RPILD (n=31, 4.441±1.706 ng/mL). The sCXCL16 levels were positively correlated with levels of serum ferritin, C reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, hydroxybutyrate dehydrogenase, and negatively correlated with peripheral lymphocytes percentage, but showed no correlation with levels of anti-melanoma differentiation-associated gene 5 antibody, Krebs von den Lungen‐6 or creatine kinase. Multivariable analysis showed that elevated sCXCL16 was an independent prognostic factor for poor prognosis of RPILD in patients with DM. The 2‐year survival rate was significantly lower in patients with high sCXCL16 level than in those with low sCXCL16 level. Conclusion A higher serum sCXCL16 level was identified as a predictive biomarker of RPILD in patients with DM, and closely associated with poor prognosis.
rheumatology
What problem does this paper attempt to address?